Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.40 |
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012057 | 0.86 | ADORA2A (0.40) | TYK2JAK2JAK1JAK3ADORA2A | |
| SCHEMBL3022043 | 0.85 | MEN1 (0.41) | BTKTYK2JAK2JAK1JAK3 | |
| SCHEMBL3531518 | 0.81 | MAP3K12 (0.42) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL3013419 | 0.79 | BTK (0.44) | BTKTYK2JAK2JAK1JAK3 | |
| SCHEMBL3533740 | 0.79 | BTK (0.44) | BTKTYK2JAK2JAK1JAK3 | |
| SCHEMBL3017869 | 0.77 | CA12 (0.42) | BTKJAK1MEN1KMT2AL3MBTL3 | |
| SCHEMBL3527086 | 0.76 | NPC1 (0.44) | JAK2JAK1 | |
| SCHEMBL3530855 | 0.71 | BTK (0.42) | BTKCHEK1JAK1CDK2AP1PRKCI | |
| SCHEMBL3017898 | 0.71 | CDK2 (0.51) | BTKCHEK1JAK2JAK1CDK2AP1 | |
| SCHEMBL3528785 | 0.69 | CDK2 (0.36) | TYK2JAK2JAK3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | BTK 316/4885CHEK1 210/4885ACP1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.